歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > Angiogenesis > LDN193189 (Hydrochloride)

瀏覽歷史

S80068

LDN193189 (Hydrochloride)

源葉(MedMol) 99%
  • 英文名:
  • LDN193189 (Hydrochloride)
  • 別名:
  • 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline hydrochloride; 3,5-Heptanedione,4-[6-(1,3-benzodioxol-5-yloxy)hexyl]; 4-[6-(3,4-Methylenedioxyphenoxy)hexyl]-3,5-heptanedione;
  • CAS號(hào):
  • 1062368-62-0
  • 分子式:
  • C25H26Cl4N6
  • 分子量:
  • 552.3261
  • 核磁/質(zhì)譜:
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車(chē)...
源葉(MedMol) S80068-1mg 99% ¥206.00元 7 - - - EA 加入購(gòu)物車(chē)
源葉(MedMol) S80068-5mg 99% ¥465.00元 3 - - - EA 加入購(gòu)物車(chē)
源葉(MedMol) S80068-10mg 99% ¥578.00元 5 - - - EA 加入購(gòu)物車(chē)
源葉(MedMol) S80068-25mg 99% ¥935.00元 6 - - - EA 加入購(gòu)物車(chē)
源葉(MedMol) S80068-50mg 99% ¥1700.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車(chē)
大包裝詢(xún)價(jià)

提交您的電話(huà)號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)(1篇)

質(zhì)檢證書(shū)(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說(shuō)明書(shū)。
  • 產(chǎn)品描述: LDN193189 hydrochloride is a selective BMP type I receptor kinases inhibitor.
  • 靶點(diǎn): ALK
  • 體外研究:
    LDN193189 potently inhibits BMP4-mediated Smad1, Smad5 and Smad8 activation with IC50 of 5 nM, and efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. Furthermore, LDN193189 also shows the inhibitory effect on the transcriptional activity induced by either constitutively active ALK2R206H or ALK2Q207D mutant proteins.A recent study shows that LDN-193189 blocks the production of reactive oxygen species induced by oxidized LDL during atherogenesis in human aortic endothelial cells
  • 體內(nèi)研究:
    In conditional caALK2-transgenic mice with Ad.Cre on on postnatal day 7 (P7), LDN-193189 (3 mg/kg i.p) leads to mild calcifications surrounding the left tibia and fibula first visible at P13, and prevents radiographic lesions at P15 without causing weight loss or growth retardation, spontaneous fractures, decreased bone density or behavioral abnormalities.LDN193189 dorsalizes zebrafish embryos by inhibiting signaling pathways induced by bone morphogenetic protein (BMP)6 without effect on vascular development.In PCa-118b tumor-bearing mice, LDN-193189 treatment attenuates tumor growth and reduces bone formation in the tumors.In LDL receptor-deficient (LDLR-/-) mice, LDN-193189 potently inhibits development of atheroma. Moreover, LDN-193189 also exhibits the inhibitory effects on associated vascular inflammation, osteogenic activity, and calcification.
  • 細(xì)胞實(shí)驗(yàn): Concentrations: 3 μM
  • 參考文獻(xiàn):
    1. Derwall M, et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol, 2012, 32(3), 613-622. 2. Lee YC, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res, 2011, 71(15), 5194-5203. 3. Cannon JE, et al. Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists. Br J Pharmacol, 2010, 161(1), 140-149. 4. Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 1.811 ml 9.053 ml 18.105 ml
    5 mM 0.362 ml 1.811 ml 3.621 ml
    10 mM 0.181 ml 0.905 ml 1.811 ml
    50 mM 0.036 ml 0.181 ml 0.362 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶(hù)參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷(xiāo)售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷(xiāo)售條款。